{{Drugbox
| Watchedfields = changed
| verifiedrevid = 470477095
| IUPAC_name = (''Z'')-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-''N'',''N''-dimethylethanamine
| image = Tamoxifen2DACS.svg
| width =
| image2 = Tamoxifen-3D-balls.png
| width2 =

<!--Clinical data-->
| tradename = Nolvadex, Genox, Tamifen, others<ref>{{cite web|title=NCI Drug Dictionary|url=http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=42901|accessdate=28 November 2015|archive-date=2015-12-08|archive-url=https://web.archive.org/web/20151208154459/http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=42901|dead-url=no}}</ref>
| Drugs.com = {{drugs.com|monograph|tamoxifen-citrate}}
| MedlinePlus = a682414
| pregnancy_AU = B3
| pregnancy_US = D
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| protein_bound = 99%
| metabolism = [[肝臟|肝臟]] ([[CYP3A4|CYP3A4]], [[CYP2C9|2C9]] and [[CYP2D6|2D6]])
| elimination_half-life = 5-7 days<ref>{{cite web | title = Tamoxifen | url = http://www.drugs.com/pro/tamoxifen.html | work = Drugs.com | accessdate = 2017-03-15 | archive-date = 2019-05-16 | archive-url = https://web.archive.org/web/20190516103916/https://www.drugs.com/pro/tamoxifen.html | dead-url = no }}</ref>
| excretion = Faeces (65%), urine (9%)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 10540-29-1
| ATC_prefix = L02
| ATC_suffix = BA01
| PubChem = 2733526
| IUPHAR_ligand = 1016
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00675
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2015313
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 094ZI81Y45
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08559
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 41774
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 83

<!--Chemical data-->
| C=26 | H=29 | N=1 | O=1
| molecular_weight = 371.515 g/mol<br>563.638 g/mol ([[檸檬酸|檸檬酸]]鹽)
| SMILES = CN(C)CCOc1ccc(cc1)/C(c2ccccc2)=C(/CC)c3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NKANXQFJJICGDU-QPLCGJKRSA-N
}}
{{medical}}
'''諾瓦得士'''或'''太莫西芬'''（Tamoxifen，簡稱'''TMX'''），常見商品名'''Nolvadex'''，可用於治療或預防[[乳癌|乳癌]]<ref name="NCI2015">{{cite web|title=Tamoxifen Citrate|url=http://www.cancer.gov/about-cancer/treatment/drugs/tamoxifencitrate|website=NCI|accessdate=28 November 2015|date=August 26, 2015|archive-date=2016-01-04|archive-url=https://web.archive.org/web/20160104184533/http://www.cancer.gov/about-cancer/treatment/drugs/tamoxifencitrate|dead-url=no}}</ref>，目前仍在研究本品對於其他[[癌症|癌症]]的效果<ref name="NCI2015" />。本品可用來治療 {{tsl|en|Albright syndrome|馬－亞二氏症|馬－亞二氏症}}。諾瓦得士治療乳癌的療程通常為每日口服，持續五年。<ref name="AHFS2015">{{cite web|title=Tamoxifen Citrate|url=http://www.drugs.com/monograph/tamoxifen-citrate.html|work=The American Society of Health-System Pharmacists|accessdate=27 Nov 2015|archive-date=2017-09-09|archive-url=https://web.archive.org/web/20170909005156/https://www.drugs.com/monograph/tamoxifen-citrate.html|dead-url=no}}</ref>對於Estrogen receptor-positive的男性乳癌患者而言，標準的內分泌治療是以 tamoxifen 治療 5-10 年，治療時間的長短會因個人差異(如復發風險和副作用等)而有所不同。此外，轉移性乳癌患者使用 tamoxifen 輔助治療後有較佳的生存率。<ref name="#1">{{cite journal |author1=Sharon H. Giordano, M.D., M.P.H. |title=Breast cancer in men |journal=The New England Journal of Medicine |date=June 14, 2018 |pages=2316 |url=https://www.nejm.org/doi/full/10.1056/NEJMra1707939 |accessdate=2020-12-14}}</ref>

嚴重副作用包含[[子宮癌|子宮癌]]、[[中風|中風]]、視力問題，以及[[肺栓塞|肺栓塞]]。常見副作用包含亂經、體重減輕，以及[[潮熱|潮熱]]。[[妊娠|妊娠]]及[[哺乳|哺乳]]期間用藥會傷害胎兒<ref name="AHFS2015" />。男性使用 tamoxifen 的副作用可能包括靜脈栓塞、白內障、性功能不全、情緒低落、睡眠障礙、潮紅和腿部抽筋<ref name="#1"/>，使病患依照醫囑服用藥物的意願降低，所以未能完整治療。<ref>{{cite journal |author1=E. Wibowo |author2=P. A. Pollock |author3=N. Hollis |author4=R. J. Wassersug |title=Tamoxifen in men: a review ofadverse events |date=2016-03-12 |pages=779 |accessdate=2020-12-14}}</ref>本品屬於[[選擇性雌激素受體調節物|選擇性雌激素受體調節物]] （SERM），可減少乳房細胞的增生，並增加抑制乳腺的因子<ref name="AHFS2015" /><ref>{{cite web|title=Selective estrogen receptor modulators|url=http://www.drugs.com/drug-class/selective-estrogen-receptor-modulators.html|accessdate=28 November 2015|archive-date=2017-05-01|archive-url=https://web.archive.org/web/20170501153137/https://www.drugs.com/drug-class/selective-estrogen-receptor-modulators.html|dead-url=no}}</ref>。本品在化學結構上歸為 [[三苯乙烯|三苯乙烯]]類化合物。<ref>{{cite book|last1=Dueñas-Díez|first1=edited by Antonio Cano Sanchez, Joaquim Calaf i Alsina, José-Luis|title=Selective Estrogen Receptor Modulators a New Brand of Multitarget Drugs|date=2006|publisher=Springer-Verlag Berlin Heidelberg|location=Berlin, Heidelberg|isbn=9783540347422|page=52|url=https://books.google.co.jp/books?id=heJDAAAAQBAJ&pg=PA52|access-date=2017-03-15|archive-date=2017-09-08|archive-url=https://web.archive.org/web/20170908201110/https://books.google.co.jp/books?id=heJDAAAAQBAJ&pg=PA52|dead-url=no}}</ref>

諾瓦得士於1967年首次發現，並列名於 [[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]，為基礎公衛體系必備藥物之一。本品屬於[[通用名药物|通用名药物]]，在[[開發中國家|開發中國家]]每日劑量批發價約0.07至0.23美金。<ref>{{cite web|title=Tamoxifen Citrate|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=TAM20T&s_year=2014&year=2014&str=20%20mg&desc=Tamoxifen%20Citrate&pack=new&frm=TAB-CAP&rte=PO&class_code2=08%2E3%2E&supplement=&class_name=%2808%2E3%2E%29Hormones%20and%20antihormones%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=28 November 2015|archive-date=2016-01-09|archive-url=https://web.archive.org/web/20160109193332/http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=TAM20T&s_year=2014&year=2014&str=20%20mg&desc=Tamoxifen%20Citrate&pack=new&frm=TAB-CAP&rte=PO&class_code2=08%2E3%2E&supplement=&class_name=%2808%2E3%2E%29Hormones%20and%20antihormones%3Cbr%3E|dead-url=yes}}</ref>在美國每日劑量約為2美金<ref name="Jordan_2006">{{cite journal | vauthors = Jordan VC | title = Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer | journal = British Journal of Pharmacology | volume = 147 Suppl 1 | issue = Suppl 1 | pages = S269-76 | date = Jan 2006 | pmid = 16402113 | pmc = 1760730 | doi = 10.1038/sj.bjp.0706399 }}</ref>。

== 参考文献 ==
{{reflist|35em}}

==外部連結==
* {{dmoz|Health/Pharmacy/Drugs_and_Medications/T/Tamoxifen/}}

[[Category:前药|Category:前药]]
[[Category:化学预防剂|Category:化学预防剂]]
[[Category:阿斯利康制药|Category:阿斯利康制药]]
[[Category:IARC第1类致癌物质|Category:IARC第1类致癌物质]]
[[Category:情绪稳定剂|Category:情绪稳定剂]]
[[Category:芳香醚|Category:芳香醚]]
[[Category:選擇性雌激素受體調節物|Category:選擇性雌激素受體調節物]]
[[Category:三苯乙烯|Category:三苯乙烯]]